Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2006

View Archived Issues

Pentavalent human-bovine vaccine reduces rotavirus gastroenteritis

Suberoylanilide hydroxamic acid active in lymphoma patients

Synbiotics maintain gut environment in severe SIRS patients

Update on biomarkers in breast cancer

Toyama outlicenses Korean rights for T-3811 to Dong-A

Promising preclinical results in Duchenne muscular dystrophy at VASTox

GemVax and Ulleval University Hospital collaborate on translational research

New subcutaneous formulation of Genasense investigated

Migenix profiles pipeline progress

Clinical candidate selected from Array BioPharma and AstraZeneca collaboration

Eurand inlicenses novel analgesic compounds from Italian universities

Can-Fite BioPharma signs CRADA with NIH for A3 adenosine receptor agonists

Posiphen completes first phase I study for Alzheimer's disease progression

New phase I study investigates PR-104 to treat hypoxic tumors

Curis updates phase I basal cell carcinoma study

Pfizer updates Canadian safety information for Macugen

New pegylated wortmannin conjugates demonstrate antitumor activity

LAB CGRP, safe with no serious adverse events in phase I study

Japanese approval for Plavix

Approvable letter for Yaz

GW-3965 protects against endotoxic liver injury and dysfunction

Novel agents for treating endocrine-related disorders disclosed in recent patents

Recent Vertex patent reports new agents for cystic fibrosis

Antiarrhythmic agents emerge from AstraZeneca R&D

Erectile dysfunction medications may be associated with increased risk of optic nerve damage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...